top of page
NEWS
Filter posts by:
Dec 10
We Work For Health Statement in Support of Biosimilars Legislative Solution
We Work For Health Executive Director Dan Leonard released the following statement in support of recently introduced legislation that...
Nov 12
Senate Judiciary Committee Considered Key Bills to Support IP Rights and Encourage Patent Investment
As Congress returned to Washington, the Senate Judiciary Committee held a full committee hearing to consider a number of critical bills...
Oct 9
New Study: Patients Unlikely to See Out-Of-Pocket Drug Savings from IRA
Washington, DC – New research contradicts promises of savings at the pharmacy counter for Medicare beneficiaries from the Inflation...
Oct 9
New Report Provides Critical Context to Government Claims of IRA So-Called Drug Savings and Explores the Law’s True Impact on Patient Costs
New research from the IQVIA Institute for Human Data Science further confirms what We Work For Health (WWFH) and others have warned...
Sep 30
Recognizing the Hatch-Waxman Act’s 40th Anniversary on Capitol Hill
The Drug Price Competition and Patent Term Restoration Act, more commonly known as the Hatch-Waxman Act, profoundly changed the...
Sep 19
We Work For Health Urges Senate HELP Committee to Reject Bills that Undermine IP and Patent Protections
Dear Chairman Sanders, Ranking Member Cassidy, and Members of the Committee: The American medical innovation infrastructure that has...
Sep 16
Fact Checking the Inflation Reduction Act’s Real-World Impact and Consequences
As healthcare access and costs continue to dominate political conversations, the flaws in the Inflation Reduction Act are becoming...
Sep 8
Hatch-Waxman Act: Celebrating 40 Years of a Balanced and Innovative Drug Ecosystem
In 1984, the Hatch-Waxman Act – formally known as the bipartisan Drug Price Competition and Patent Term Restoration Act – established a...
bottom of page